Dr. Reddy`s Laboratories 

₹6,636.3
125
-₹15.7-0.24% 今天

統計

當日最高
-
當日最低
-
52週最高
-
52週最低
-
成交量
-
平均成交量
-
市值
1.11T
市盈率
20
股息收益率
0.6%
股息
39.91

即將到來

股息

0.6%股息收益率
10年增長
8.31%
5年增長率
14.87%
3年增長率
16.96%
1年增長率
N/A

收益

25Oct預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
54.16
64.01
73.86
83.71
預期每股收益
83.25133912193884
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 DRREDDY.NSE 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Show more...
首席執行官
Mr. Gunupati Venkateswara Prasad B.E.
員工
27048
國家
IN
ISIN
INE089A01023

上市公司